Shared on 31 Oct 25

Fair value Increased 2.42%

AstraZeneca's analyst-derived fair value has been raised to $144.38 per share from $140.96. This reflects modest increases in pipeline confidence and anticipated revenue growth, as noted by analysts in recent research updates.

Shared on 17 Oct 25

Fair value Increased 2.03%

AstraZeneca's analyst price target has been raised from £138.16 to £140.96. This reflects a modest increase as analysts highlight both expanding potential for key pipeline products and a tempered outlook on patent risk and competitive pressures in certain therapeutic areas.

Shared on 03 Oct 25

Fair value Increased 2.61%

AstraZeneca’s analyst price target has been raised from $93 to $99. Analysts cite stronger pipeline progress and improved revenue growth forecasts as key factors for the upward revision.

Shared on 17 Sep 25

Fair value Decreased 1.36%

Despite ongoing pipeline successes that support long-term topline growth, the consensus price target for AstraZeneca has been revised slightly lower to £134.64 due to concerns over execution in recent Wainua sales. Analyst Commentary Bullish analysts have raised long-term revenue forecasts for AstraZeneca due to substantial pipeline progress year-to-date, expecting stronger topline growth through 2030.

Shared on 30 Aug 25

Fair value Decreased 1.01%

Despite ongoing pipeline progress and bullish long-term forecasts, AstraZeneca’s consensus price target was revised modestly downward to £135.55, as analysts balanced positive R&D developments against short-term revenue headwinds and market reactions. Analyst Commentary Bullish analysts increased long-term revenue forecasts, citing substantial pipeline progress achieved this year.